Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa

AIDS

Volumn 25, Issue 14, 2011, Pages 1727-1735

  Matthews, Gail V ^a   Manzini, Prince ^b   Hu, Zonghui ^c   Khabo, Paul ^b   Maja, Patrick ^b   Matchaba, Gugu ^b   Sangweni, Phumele ^b   Metcalf, Julie ^c   Pool, Nicholaas ^d   Orsega, Susan ^c   Emery, Sean ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b South African National Defence Force   (South Africa)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d Bio Analytical Research Corporation PTY LTD   (South Africa)

Author keywords

hepatitis B; HIV; lamivudine; mortality; randomized controlled trial; South Africa

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; DIDANOSINE; LAMIVUDINE; STAVUDINE; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; COMBINATION CHEMOTHERAPY; DISEASE EXACERBATION; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOUTH AFRICA; THROMBOCYTE COUNT;

ADULT; AFRICA, SOUTHERN; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DIDANOSINE; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HIV-1; HUMANS; KAPLAN-MEIER ESTIMATE; LAMIVUDINE; MALE; STAVUDINE; TREATMENT OUTCOME;

EID: 80052403045     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328349bbf3     Document Type: Article

References (30)

1. Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, Kirk O, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166:1632-1641. (Pubitemid 44232373)
2. Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32:492-497. (Pubitemid 32173638)
3. Salmon-Ceron D, Lewden C, Morlat P, Bevilacqua S, Jougla E, Bonnet F, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol 2005; 42:799-805. (Pubitemid 40693195)
4. Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Munoz A, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360:1921-1926. (Pubitemid 35472132)
5. Benhamou Y, Fleury H, Trimoulet P, Pellegrin I, Urbinelli R, Katlama C, et al. Antihepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology 2006; 43:548-555.
6. Nelson M, Portsmouth S, Stebbing J, Atkins M, Barr A, Matthews G, et al. An open-label study of tenofovir in HIV-1 and hepatitis B virus co-infected individuals. AIDS 2003; 17:F7-F10. (Pubitemid 36106292)
7. Matthews GV, Cooper DA, Dore GJ. Improvements in parameters of end-stage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir. Antivir Ther 2007; 12:119-122. (Pubitemid 46340434)
8. Nunez M, Perez-Olmeda M, Diaz B, Rios P, Gonzalez-Lahoz J, Soriano V. Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. AIDS 2002; 16:2352-2354. (Pubitemid 35449029)
9. Matthews GV, Seaberg E, Dore GJ, Bowden S, Lewin SR, Sasadeusz J, et al. Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals. AIDS 2009; 23:1707-1715.
10. Mallet VO, Dhalluin-Venier V, Verkarre V, Correas JM, Chaix ML, Viard JP, et al. Reversibility of cirrhosis in HIV/HBV coinfection. Antivir Ther 2007; 12:279-283. (Pubitemid 46569914)
11. Maida I, Soriano V, Castellares C, Ramos B, Sotgiu G, Martin-Carbonero L, et al. Liver fibrosis in HIV-infected patients with chronic hepatitis B extensively exposed to antiretroviral therapy with anti-HBV activity. HIV Clin Trials 2006; 7:246-250. (Pubitemid 44963808)
12. Brook G, Main J, Nelson M, Bhagani S, Wilkins E, Leen C, et al. British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010. HIV Med 2010; 11:1-30.
13. Soriano V, Puoti M, Peters M, Benhamou Y, Sulkowski M, Zoulim F, et al. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS 2008; 22:1399-1410.
14. DHSS. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents; 2011. http://aidsinfonihgov/contentfiles/ AdultandAdolescentGL.pdf
15. Dore GJ, Cooper DA, Barrett C, Goh LE, Thakrar B, Atkins M, et al. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. J Infect Dis 1999; 180:607-613. (Pubitemid 29411344)
16. Ratsela A, Polis M, Dhlomo S, Emery S, Grandits G, Khabo P, et al. A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count
17. Rouet F, Chaix ML, Inwoley A, Msellati P, Viho I, Combe P, et al. HBV and HCV prevalence and viraemia in HIV-positive and HIV-negative pregnant women in Abidjan, Cote d'Ivoire: the ANRS 1236 study. J Med Virol 2004; 74:34-40. (Pubitemid 38988857)
18. Sutcliffe S, Taha TE, Kumwenda NI, Taylor E, Liomba GN. HIV-1 prevalence and herpes simplex virus 2, hepatitis C virus, and hepatitis B virus infections among male workers at a sugar estate in Malawi. J Acquir Immune Defic Syndr 2002; 31:90-97.
19. Matee MI, Magesa PM, Lyamuya EF. Seroprevalence of human immunodeficiency virus, hepatitis B and C viruses and syphilis infections among blood donors at the Muhimbili National Hospital in Dar es Salaam, Tanzania. BMC Public Health 2006; 6:21.
20. Diop-Ndiaye H, Toure-Kane C, Etard JF, Lo G, Diaw P, Ngom-Gueye NF, et al. Hepatitis B, C seroprevalence and delta viruses in HIV-1 Senegalese patients at HAART initiation (retrospective study). J Med Virol 2008; 80:1332-1336. (Pubitemid 351897402)
21. Hoffmann CJ, Fielding KL, Charalambous S, Sulkowski MS, Innes C, Thio CL, et al. Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events. AIDS 2008; 22:67-74. (Pubitemid 350294879)
22. De Luca A, Bugarini R, Lepri AC, Puoti M, Girardi E, Antinori A, et al. Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. Archiv Intern Med 2002; 162:2125-2132. (Pubitemid 35168221)
23. Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19:593-601. (Pubitemid 40543982)
24. Law WP, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham K, Lange JM, et al. Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS 2004; 18:1169-1177. (Pubitemid 38738516)
25. Hoffmann CJ, Charalambous S, Martin DJ, Innes C, Churchyard GJ, Chaisson RE, et al. Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis 2008; 47:1479-1485.
26. Idoko J, Meloni S, Muazu M, Nimzing L, Badung B, Hawkins C, et al. Impact of hepatitis B virus infection on human immunodeficiency virus response to antiretroviral therapy in Nigeria. Clin Infect Dis 2009; 49:1268-1273.
27. Hoffmann CJ, Charalambous S, Thio CL, Martin DJ, Pemba L, Fielding KL, et al. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS 2007; 21:1301-1308. (Pubitemid 46883484)
28. Matthews GV, Avihingsanon A, Lewin SR, Amin J, Rerknimitr R, Petcharapirat P, et al. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand. Hepatology 2008; 48:1062-1069.
29. Dore GJ, Cooper DA, Pozniak AL, DeJesus E, Zhong L, Miller MD, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and-experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004; 189:1185-1192. (Pubitemid 38457242)
30. World Health Organisation. Rapid advice: antitretroviral therapy for HIV infection in adults and adolescents; 2009. www.who.int/hiv/pub/arv/rapid-advice- art.pdf